Zaffaroni Mauro, Rizzo Annalisa, Baldini Silvana Maria, Ghezzi Angelo, Comi Giancarlo
Centro Studi Sclerosi Multipla, Gallarate, Italy.
Neurol Sci. 2008 Sep;29 Suppl 2:S230-2. doi: 10.1007/s10072-008-0946-x.
We retrospectively analyzed data from 70 multiple sclerosis (MS) patients treated with mitoxantrone (MX) before Interferon-beta (IFN-beta) because of clinically and MRI very active isolated syndrome (CIS) or relapsing-remitting MS (induction therapy) or due to breakthrough/persistently active disease in spite of IFN-beta (add-on/combination therapy), or for increased disability suggesting a secondary progression (rescue therapy). After almost 2-year follow-up, relapse rate and disability decreased very significantly in the two former groups while MX was essentially ineffective as rescue therapy. Induction therapy is a valid option for very aggressive/active CIS and MS at onset.
我们回顾性分析了70例多发性硬化症（MS）患者的数据，这些患者因临床和MRI显示为非常活跃的孤立综合征（CIS）或复发缓解型MS（诱导治疗），或尽管接受了干扰素-β（IFN-β）治疗但仍有疾病突破/持续活跃（附加/联合治疗），或因残疾加重提示继发进展（挽救治疗），而在使用干扰素-β之前接受了米托蒽醌（MX）治疗。经过近2年的随访，前两组的复发率和残疾程度显著下降，而MX作为挽救治疗基本无效。诱导治疗对于起病时非常侵袭性/活跃的CIS和MS是一种有效的选择。
